Valneva Completes BLA Submission for Chikungunya Vaccine

Valneva has completed its biologics license application (BLA) to the FDA for its investigational vaccine for chikungunya, a mosquito-borne illness that often includes fever and joint pain.

In clinical trials, the single-dose vaccine generated protective levels of neutralizing antibodies one month after vaccination in 98.9 percent of participants. There are currently no approved vaccine for the viral infection, which is most frequently found in Africa, Asia and India.

The company is seeking FDA approval of the vaccine candidate for adults 18 years and older. VLA1553 previously received Breakthrough Therapy and Fast Track designations.